POSTER PRESENTATION

Open Access

Immuno-imaging and -therapy in ovarian cancer and sarcoma with de novo single-chain fv-fc fusion protein targeting TEM1/CD248

Chunsheng Li^{1*}, Junying Wang¹, Efthymia Iliana Matthaiou¹, Yi Guo¹, Jia Hu¹, Ann Marie Chacko², Vladimir R Muzykantov², George Coukos^{1,3}

From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014

Tumor Endothelial Marker 1 (TEM1 or CD248) has been identified as a microvascular marker of tumor angiogenesis in various human cancers. By comparing the vasculature of ovarian cancer and normal ovary, we and others [1] identified that TEM1 is overexpressed in tumor microenvironment in ovarian cancer and it could be suggested as a suitable marker for targeting tumor vasculature of cancer therapeutics. In addition, we also confirmed that TEM1 is overexpressed in cancer cells in most soft tissue sarcoma patients.

To better assist TEM1-specific theranostics, we sought to develop TEM1-specific affinity agents. From previously isolated TEM1-specific single chain antibody, scFv78 [2], we developed a panel of new multivalent variants of scFv78 to improve the thermal, serum stability and avidity. The variants includes a dimeric Fc fusion (from hu IgG1), a tetrameric CH2 fusion, a dimeric CH3 fusion and a dimeric (Fab)2 fusion. This panel was produced using mammalian cells and affinity purified from culture supernatant. The protein of scFv78-Fc exhibited higher affinity ($KD = 0.14 \pm 0.01nM$, 15 fold higher of parental scFv78) to the target protein in live cell ELISA assay. Using the preclinical tumor vascular models we developed [3,4], pharmacokinetics and biodistribution studies in revealed that the scFv78Fc has extended serum half-life. Near infrared (NIR) immuno-imaging [5] and 124I-immunoPET imaging with scFv78-Fc demonstrated that such tracers were enriched in TEM1-positive tumors but not normal organs. In addition, scFv78Fc was conjugated to Monomethyl auristatin E (MMAE) and saporin to develop potent TEM1-targeting immunotoxins, which showed

TEM1-specific toxicity in vitro and in preclinical animal models. Lastly, TEM1-targeted nanomedicine platform was developed and studied in vitro [6] and in several pre-clinical tumor models. scFv78-Fc targeted, shikonin-loaded PLGA nanoparticles showed higher accumulation and killing efficacy at the TEM1 positive tumors, compared to free drug and unarmed nanoparticle controls.

Taken together, our data indicate that the scFv78-Fc is suitable for development as targeted therapeutics and imaging for cancers such as ovarian cancer and sarcomas. Based upon these findings, we propose to use the immuno-imaging for detection and selection of patients suitable for immune therapies with the TEM1-targeted immunotoxin or nanoparticles; and for monitoring the efficacy of such therapies.

Authors' details

¹Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA. ²Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA. ³Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.

Published: 6 November 2014

References

1. Conejo-Garcia JR, Buckanovich RJ, Benencia F, et al: Vascular leukocytes contribute to tumor vascularization. *Blood* 2005, **105**:679-81.
2. Zhao A, Nunez-Cruz S, Li C, et al: Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform. *J Immunol Methods* 2011, **363**:221-32.
3. Chacko AM, Li C, Nayak M, et al: Development of 124I Immuno-PET Targeting Tumor Vascular TEM1/Endosialin. In *Journal of nuclear medicine : official publication. Volume 55*. Society of Nuclear Medicine; 2014:500-7.
4. Li C, Chacko AM, Hu J, et al: Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model. *Cancer biology & therapy* 2014, **15**.

¹Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA

Full list of author information is available at the end of the article

5. Li C, Wang J, Hu J, *et al*: Development, Optimization, and Validation of Novel anti-TEM1/CD248 Affinity Agent for Optical Imaging in Cancer. *Oncotarget* 2014.
6. Matthaiou E, Barar J, Sandaltzopoulos R, *et al*: Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. *International Journal of Nanomedicine* 2014, **9**.

doi:10.1186/2051-1426-2-S3-P219

Cite this article as: Li *et al*: Immuno-imaging and -therapy in ovarian cancer and sarcoma with de novo single-chain fv-fc fusion protein targeting TEM1/CD248. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P219.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit